Q-omics provides the consensus-scored ZC3HAV1L profile across patient tissues and cancer cell-line models. ZC3HAV1L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZC3HAV1L is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ZC3HAV1L protein abundance shows 21,668 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, COAD, and LSCC as cancer lineages where ZC3HAV1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3HAV1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3HAV1L survival associations across molecular data types. ZC3HAV1L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3HAV1L RNA expression–survival associations across cancer types. High ZC3HAV1L expression shows unfavorable associations in CESC, ACC, MESO, KIRP, LGG and BLCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ZC3HAV1L RNA expression.
This table summarizes ZC3HAV1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZC3HAV1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3HAV1L shows higher tumor expression in COAD, KIRC, LUAD, KIRP, HNSC and BLCA. The COAD box plot shows higher ZC3HAV1L RNA expression in tumor versus normal tissue (log2 FC = +2.385, t-test p < 0.001).
This table shows molecular features associated with ZC3HAV1L in patient tissues and cancer cell lines. In patient samples, ZC3HAV1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3HAV1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
